As IIPs are heterogenous group of unknown<unk>  lung disease with different natural history and clinical course, their management should be based on the clinical subtype. Optimal<unk>  for IPF is controversial as all currently available medications for IPF are severely limited by the lack of clear understanding of the natural history of IPF, the presence of various forms of study designs; heterogeneous patient groups, disputable diagnostic certainty; variable study duration; differences in medication formulation, dosage, route of administration, and duration of treatment; lack of placebo controls; variable intervals between evaluations and differing types of non quantitative assessment criteria. To date, most of treatment strategies have been based on eliminating or suppressing the inflammatory component. As no pharmacological<unk>  has been proven a clinical efficacy in altering or reversing the inflammatory process of IPF. The clinical trials over the past decades are hopefully held to clear the controversial dilemmas regarding which patients should be treated? When should<unk>  be started? What is the best treatment and how it should delivered and maintained? and how can be the treatment monitored especially that majority of patients are suffering comorbidities related functional limitations.
Idiopathic interstitial pneumonia medical therapy
Idiopathic pulmonary fibrosis medical therapy
Pulmonary nodule medical therapy
Bronchiolitis medical therapy
Hypersensitivity pneumonitis medical therapy
Bronchiectasis medical therapy
Eosinophilic pneumonia medical therapy
Alpha 1-antitrypsin deficiency medical therapy